|
Supplement No. 3 Dated November 6, 2014 (To Prospectus dated April 29, 2014) |
Rule 424(b)(3) Registration No. 333-189337 |
This prospectus supplement (“Supplement”) modifies, supersedes and supplements information contained in, and should be read in conjunction with, that certain prospectus, dated April 29, 2014 and as supplemented and amended to date (“Prospectus”), of DelMar Pharmaceuticals, Inc. This Supplement is not complete without, and may not be delivered or used except in connection with, the original Prospectus.
The information included in this Supplement modifies and supersedes, in part, the information in the Prospectus. Any information that is modified or superseded in the Prospectus shall not be deemed to constitute a part of the Prospectus, except as modified or superseded by this Supplement.
We may amend or supplement the Prospectus from time to time by filing amendments or supplements as required. You should read the entire Prospectus and any amendments or supplements carefully before you make an investment decision.
See “Risk Factors” beginning on page 2 of the prospectus dated April 29, 2014, for risk factors and information you should consider before you purchase shares.
Recent Developments
Effective October 31, 2014, the Company entered into election to exercise warrants agreements (the “Investor Warrant Amendments”) with certain holders of Investor Warrants, pursuant to which the Company reduced the exercise price from $0.80 to $0.65 per share for 1,136,347 Investor Warrants, and in accordance with the agreements, the holders of such Investor Warrants exercised the Investor Warrants for cash at the foregoing reduced exercise price, such that the Company received aggregate gross proceeds from such exercises of $738,626. Previously, in September 2014, pursuant to election to exercise warrant agreements, the Company reduced the exercise price from $0.80 to $0.65 of 87,500 Investor Warrants, and the holders of such Investor Warrants exercised such Investor Warrants for cash in accordance with such agreements, such that the Company received aggregate gross proceeds of $56,875 from such exercises.
The selling stockholders who exercised their Investor Warrants pursuant to the foregoing consist of the following:
| Selling Stockholder | Number of Investor Warrants Exercised | Number of Investor Warrants Remaining |
| Daniel Coiro | 62,500 | 0 |
| John Ricotta | 25,000 | 0 |
| Stephanie Gillespie | 5,000 | 6,288 |
| Barry Magnus | 25,000 | 0 |
| DCG & T TTEE FBO Raymond Coppede R/O IRA | 125,000 | 0 |
| Michael Bonevento | 62,500 | 0 |
| Craig Fielder | 100,000 | 150,000 |
| Joseph E. & Christine D. Heller JTTEN | 20,000 | 11,250 |
| David Barry | 10,000 | 7,500 |
| Richard Grossbard | 93,750 | 0 |
| Michael Leiter | 75,000 | 74,750 |
| Lance Siegall | 50,000 | 0 |
| DCG & T TTEE FBO John Dempsey IRA | 50,000 | 0 |
| Deepak H. Aggarwal | 30,000 | 20,000 |
| John D. Marx | 15,384 | 59,241 |
| Deck F. Couch | 26,500 | 36,000 |
| Akita Capital LLC | 31,250 | 0 |
| Lawrence Grossbard | 100,000 | 110,125 |
| Brian and Debbie Keller | 17,000 | 14,250 |
| Omnibus S.A. | 299,963 | 0 |
In August 2014, certain holders of Dividend Warrants transferred their Dividend Warrants to third parties. Following such transfer, the holders of the Dividend Warrants consist of the following:
| Selling Stockholder | Number of Dividend Warrants |
| Alison Winter | 1,600,004 |
| Lisa Guise | 50,000 |
| Dale Associates S.A. | 1,600,003 |
Effective October 31, 2014, the Company entered into amendments (the “Dividend Warrant Amendments”) with holders of Dividend Warrants. Pursuant to the Dividend Warrant Amendments, 3,250,007 Dividend Warrants were amended to remove the provision requiring the Company to net cash settle the Dividend Warrants in the event the Company fails to timely deliver shares of common stock upon exercise, and to remove the Company’s right to redeem the Dividend Warrants.